IL6 and inflammatory bowel disease: Instead, the scientific rationale for the evaluation and implementation of IL-6 inhibitors in GIBD is mostly driven by the fact that IL-6 plays a key role in inflammatory and autoimmune processes and is supported by sparse yet promising clinical data in IBD.